Skip to main content
Equibles
PHAT logo

PHAT · Phathom Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track PHAT — free

Use PHAT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHAT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.32 +0.33 (+5.45%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$484.60M
Shares
80.90M
Volume · Oct 28 2.08M Avg daily vol (3M) 1.49M

Phathom Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Phathom Pharmaceuticals, Inc. (PHAT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Phathom Pharmaceuticals, Inc. (PHAT) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Confident tone Voquesna prescription metrics Physician access friction for Voquesna Revenue growth and profitability inflection
Revenue
$74.27M
▲ 88% YoY
Diluted EPS
$-0.21
Gross margin
79.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Phathom Pharmaceuticals, Inc. (PHAT) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Phathom Pharmaceuticals, Inc. (PHAT) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Confident tone New-to-Brand Prescription Share (NBRX) Gastroenterology Strategy Execution Total Prescription (TRX) and Refill Persistence
Revenue
$58.30M
▲ 104.4% YoY
Diluted EPS
$-0.37
Gross margin
79.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-15
Phathom Pharmaceuticals, Inc. (PHAT) April 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-26
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Confident tone Financial Performance and Guidance Vaquesna Commercial Progress Reimbursement and Access
Revenue
$57.58M*
▲ 94.1% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
Confident tone Sales Force Realignment Prescription Metrics Gastroenterology Strategic Shift
Revenue
$49.50M
▲ 202.7% YoY
Diluted EPS
$-0.41
Gross margin
87.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript
Confident tone Sales force realignment toward gastroenterologists Eosinophilic esophagitis (EoE) development BlinkRx cash pay channel and access
Revenue
$39.50M
▲ 439.4% YoY
Diluted EPS
$-1.05
Gross margin
87.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Positive tone Citizens Petition and exclusivity timeline VOQUEZNA commercial launch and revenue growth Manufacturing and tariffs
Revenue
$28.52M
▲ 1391.6% YoY
Diluted EPS
$-1.31
Gross margin
86.9%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Confident tone VOQUEZNA commercial launch and growth momentum Non-Erosive GERD approval inflection Eosinophilic esophagitis (EoE) label expansion
Revenue
$29.66M*
▲ 4249.6% YoY
Gross margin
87.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Confident tone VOQUEZNA commercial launch momentum Guidance visibility for 2025 Non-Erosive GERD label expansion
Revenue
$16.35M
Diluted EPS
$-1.32
Gross margin
85.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Confident tone VOQUEZNA launch momentum Patient testimonials and demand Physician adoption / prescriber mix
Revenue
$7.32M
Diluted EPS
$-1.56
Gross margin
81.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Confident tone BlinkRx reliance and cash-pay dynamics Nonerosive GERD label expansion opportunity Direct-to-consumer marketing campaign
Revenue
$1.91M
Diluted EPS
$-1.42
Gross margin
77.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
Confident tone VOQUEZNA launch progress Launch variability and risk Demand versus filled prescriptions
Revenue
$682,000*
Gross margin
75.5%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–17 of 17 webcasts
Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 19 filings 19 filers Visit website Investor relations